Key result
Computational heart modeling forecasts future ventricular arrhythmias in HCM with ~80% accuracy.
Why the study?
Current clinical risk stratification criteria inadequately identify hypertrophic cardiomyopathy patients at risk of ventricular arrhythmias and sudden cardiac death.
Does personalized computational heart modeling using CMR and T1 mapping improve the prediction of ventricular arrhythmias in patients with hypertrophic cardiomyopathy compared to current clinical risk predictors?
Does personalized computational heart modeling using CMR and T1 mapping improve the prediction of ventricular arrhythmias in patients with hypertrophic cardiomyopathy compared to current clinical risk predictors?
Personalized computational heart models incorporating focal and diffuse fibrosis from CMR and T1 mapping can accurately predict ventricular arrhythmia risk in HCM patients, outperforming standard clinical predictors.
Hypertrophic cardiomyopathy (HCM) causes sudden cardiac death (SCD) due to ventricular arrhythmias (VA) manifesting from myocardial fibrosis proliferation. Current clinical risk stratification criteria inadequately identify at-risk patients in need of primary prevention of VA. Here, we use mechanistic computational modeling of the heart to analyze how HCM-specific remodeling of the heart promotes arrhythmogenesis and to develop a personalized strategy to forecast risk of VAs in these patients. We combine contrast-enhanced cardiac magnetic-resonance (CMR) imaging and T1 mapping data to construct digital replicas of HCM patient hearts that represent the patient-specific distribution of focal and diffuse fibrosis and evaluate the substrate propensity to VA. Our analysis indicates that the presence of diffuse fibrosis, which is rarely assessed in these patients, increases arrhythmogenic propensity. In forecasting future VA events in HCM patients, the imaging-based computational heart approach achieved 84.6%, 76.9%, and 80.1% sensitivity, specificity, and accuracy, respectively, and significantly outperformed current clinical risk predictors. This novel VA risk assessment may have the potential to prevent SCD and help deploy primary prevention appropriately in HCM patients.
No takes yet. Share an insight, caveat, or question.
O’Hara et al. (2021) studied Hypertrophic cardiomyopathy (HCM). Imaging-based computational heart approach vs. Current clinical risk predictors was evaluated on Future ventricular arrhythmia (VA) events. An imaging-based computational heart approach achieved 84.6% sensitivity, 76.9% specificity, and 80.1% accuracy in forecasting future ventricular arrhythmia events in HCM patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: